6/19/2020

Bivalirudin Injection

Reason for the Shortage

- Accord has bivalirudin available.
- Apotex has discontinued bivalirudin.
- AuroMedics did not provide a reason for the shortage.
- Baxter has 250 mg/50 mL bivalirudin premixed bags available. The company is not actively producing the 500 mg/100 mL bags due to low demand.
- Dr. Reddy's did not provide a reason for the shortage.
- Fresenius Kabi has bivalirudin available.
- Pfizer has bivalirudin available.
- Sandoz has bivalirudin available.

Available Products

- Angiomax lyophilized powder for injection, Sandoz, 250 mg, vial, 10 count, NDC 65293-0001-01
- Bivalirudin lyophilized powder for injection, AuroMedics, 250 mg, vial, 10 count, NDC 55150-0210-10
- Bivalirudin lyophilized powder for injection, Dr. Reddy's, 250 mg, vial, 10 count, NDC 55111-0652-37
- Bivalirudin lyophilized powder for injection, Fresenius Kabi, 250 mg, vial, 10 count, NDC 63323-0562-10
- Bivalirudin lyophilized powder for injection, Pfizer, 250 mg, ADD-Vantage vial, 10 count, NDC 00409-8300-15
- Bivalirudin lyophilized powder for injection, Pfizer, 250 mg, vial, 10 count, NDC 00409-8300-10
- Bivalirudin lyophilized powder for injection, Sandoz, 250 mg, vial, 10 count, NDC 00781-3158-95
- Bivalirudin injection, Baxter, 250 mg/50 mL, premixed bag, 24 count, NDC 00338-9572-24

Estimated Resupply Dates

- All marketed presentations are available.

Updated

Updated June 19, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.